摘要
目的分析辽宁省肿瘤医院2017—2019年抗肿瘤中成药的使用情况以及变化趋势,为临床合理应用抗肿瘤中成药提供依据。方法汇总2017—2019年抗肿瘤中成药的使用数据,统计分析其销售金额,并逐年对排名前10的抗肿瘤中成药数量、品种、用药频度(DDDS)、日均费用(DDC)及药品排序比进行统计分析。结果2017—2019年抗肿瘤中成药使用金额占中成药总金额比例变化幅度不大,其中注射型始终占较大比例,口服剂型虽占比小,但呈逐年上升趋势。2017—2019年康艾注射液、舒肝宁注射液、康莱特注射液、鸦胆子油乳注射液的用药金额稳居前6位,口服中成药整体销售金额有逐年递增趋势。2017—2019年DDDS排名第1位分别为复方斑蝥胶囊、生血宝合剂、鸦胆子油软胶囊,参麦注射液、舒肝宁注射液、参芪扶正注射液的DDDS逐年递减。消癌平注射液、康艾注射液、康莱特注射液、舒肝宁注射液DDC值偏高,连续3年稳居前4位。从排序比可以看出大多数抗肿瘤中成药的排序比接近1.00,消癌平注射液、康艾注射液、康莱特注射液、舒肝宁注射液排序比远<1.00。结论抗肿瘤中成药的用药情况基本合理,其中口服型抗肿瘤中成药用药金额表现为逐年上升,注射型抗肿瘤中成药用药金额逐渐下降,在实际的临床应用中应通过药师审方、处方点评、合理用药宣教等方式规范用药行为,进而对用药风险进行有效规避。
Objective This paper analyzed the use and change trend of Chinese patent drugs for antitumor in Liaoning cancer hospital and institute from 2017 to 2019,so as to provide a basis for rational clinical application of Chinese patent drugs for anti-tumor.Methods The data of the use of Chinese patent drugs for anti-tumor in our hospital from 2017 to 2019 were summarized,and the sales amount was analyzed statistically.The number,varieties,frequency of use(DDDS),daily cost(DDC)and drug sequencing ratio of the top 10 Chinese patent drugs for anti-tumor were statistically analyzed year by year.Results From 2017 to 2019,the amount of anti-tumor proprietary Chinese medicine used in our hospital and the proportion of the total amount of proprietary Chinese medicine did not change significantly,among which the injection type always accounted for a large proportion,and the oral dosage form,although it accounted for a small proportion,showed an increasing trend year by year.From 2017 to 2019,the drug amount of Kang'ai Injection(康艾注射液),Shuganning Injection(舒肝宁注射液),Kanglaite Injection(康莱特注射液)and Brucea Javanica Oil Emulsion Injection ranked among the top 6,and the overall sales amount of oral Chinese patent medicine increased year by year.From 2017 to 2019,DDDS ranked first in Fufang Banmao Capsules(复方斑蝥胶囊),Shengxuebao Mixture(生血宝合剂),Brucea Javanica Oil Soft Capsules,and the DDDS of Shenmai Injection(参麦注射液),Shuganning Injection and Shenqi Fuzheng Injection(参芪扶正注射液)decreased year by year.The DDC values of Xiaoaiping Injection(消癌平),Kang'ai Injection,Kanglaite Injection and Shuganning Injection were relatively high,ranking the top 4 for 3 consecutive years.It can be seen from the sequencing ratio that the sequencing ratio of most of the anti-tumor patent drugs is close to 1.00,and the sequencing ratio of Xiaoaiping Injection,Kang'ai Injection,Kanglaite Injection and Shuganning Injection was far less than 1.00.Conclusion Our antitumor basic reasonable conditions of drug utilization of the proprietary Chinese medicine,Chinese medicines,including oral antineoplastic drugs amount show is rising year by year,injected antitumor proprietary Chinese medicine gradually decline,in the actual clinical application should be through the pharmacist prescriptions,prescription reviews,rational drug use education methods such as standard medical behavior,thus to effectively avoid risk.
作者
刘畅
LIU Chang(Cancer Hospital of China Medical University,Liaoning Cancer Hospital and Institute,Shengyang 110042,Liaoning,China)
出处
《辽宁中医药大学学报》
CAS
2021年第5期203-206,共4页
Journal of Liaoning University of Traditional Chinese Medicine
关键词
抗肿瘤中成药
销售金额
用药频度
日均费用
排序比
合理性
anti-tumor Chinese patent medicine
sales amount
frequency of drug use
average daily expenses
sequence ratio
rationality
